[go: up one dir, main page]

NO20092331L - LINGO-bindingsmolekyler og farmasoytisk anvendelse derav - Google Patents

LINGO-bindingsmolekyler og farmasoytisk anvendelse derav

Info

Publication number
NO20092331L
NO20092331L NO20092331A NO20092331A NO20092331L NO 20092331 L NO20092331 L NO 20092331L NO 20092331 A NO20092331 A NO 20092331A NO 20092331 A NO20092331 A NO 20092331A NO 20092331 L NO20092331 L NO 20092331L
Authority
NO
Norway
Prior art keywords
binding molecule
lingo
polynucleotide
binding molecules
pharmaceutical use
Prior art date
Application number
NO20092331A
Other languages
English (en)
Norwegian (no)
Inventor
Josef Prassler
Adrien Walmsley
William Leonard Wishart
Marta Cortes-Cros
Ingo Klagge
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38325542&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20092331(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of NO20092331L publication Critical patent/NO20092331L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
NO20092331A 2006-11-17 2009-06-17 LINGO-bindingsmolekyler og farmasoytisk anvendelse derav NO20092331L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP06124350 2006-11-17
PCT/EP2007/009880 WO2008058736A1 (en) 2006-11-17 2007-11-15 Lingo binding molecules and pharmaceutical use thereof

Publications (1)

Publication Number Publication Date
NO20092331L true NO20092331L (no) 2009-06-17

Family

ID=38325542

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20092331A NO20092331L (no) 2006-11-17 2009-06-17 LINGO-bindingsmolekyler og farmasoytisk anvendelse derav

Country Status (27)

Country Link
US (4) US8299221B2 (es)
EP (2) EP2084190B1 (es)
JP (2) JP5647414B2 (es)
KR (1) KR20090078353A (es)
CN (2) CN103351437A (es)
AR (1) AR063829A1 (es)
AT (1) ATE502960T1 (es)
AU (1) AU2007321817A1 (es)
BR (1) BRPI0718406A2 (es)
CA (1) CA2669181A1 (es)
CL (1) CL2007003303A1 (es)
CO (1) CO6180433A2 (es)
CR (1) CR10756A (es)
DE (1) DE602007013445D1 (es)
EC (1) ECSP099332A (es)
ES (1) ES2363622T3 (es)
GT (1) GT200900121A (es)
IL (1) IL198313A0 (es)
MA (1) MA30965B1 (es)
MX (1) MX2009005175A (es)
NO (1) NO20092331L (es)
PE (1) PE20081392A1 (es)
RU (1) RU2009122514A (es)
TN (1) TN2009000190A1 (es)
TW (1) TW200831534A (es)
WO (1) WO2008058736A1 (es)
ZA (1) ZA200902409B (es)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2537015T3 (es) 2003-03-19 2015-06-01 Biogen Ma Inc. Proteína de unión del receptor de NOGO
EP1776136B1 (en) 2004-06-24 2012-10-03 Biogen Idec MA Inc. Treatment of conditions involving demyelination
DK1904104T3 (da) 2005-07-08 2013-11-11 Biogen Idec Inc SP35-antistoffer og anvendelser heraf
NZ569428A (en) * 2005-12-02 2012-11-30 Biogen Idec Inc Treatment of conditions involving demyelination with a Sp35 antagonist
WO2008013782A2 (en) 2006-07-24 2008-01-31 Biogen Idec Ma Inc. Methods for promoting myelination, neuronal survival and oligodendrocyte differentiation via administration of sp35 or trka antagonists
US8128926B2 (en) 2007-01-09 2012-03-06 Biogen Idec Ma Inc. Sp35 antibodies and uses thereof
CN101980603A (zh) * 2007-10-11 2011-02-23 比奥根艾迪克Ma公司 LINGO-1和TrkB拮抗剂的用途
JP5754046B2 (ja) * 2007-11-08 2015-07-22 バイオジェン・エムエイ・インコーポレイテッドＢｉｏｇｅｎ ＭＡ Ｉｎｃ． 脱髄を伴う状態の治療におけるｌｉｎｇｏ−４アンタゴニストの使用
AU2009269099B2 (en) 2008-07-09 2016-03-10 Biogen Ma Inc. Compositions comprising antibodies to LINGO or fragments thereof
WO2011139714A2 (en) 2010-04-26 2011-11-10 Atyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of cysteinyl-trna synthetase
ES2638311T3 (es) 2010-04-27 2017-10-19 Atyr Pharma, Inc. Descubrimiento innovador de composiciones terapéuticas, diagnósticas y de anticuerpos relacionadas con fragmentos de proteína de treonil ARNt sintetasas
AU2011248614B2 (en) 2010-04-27 2017-02-16 Pangu Biopharma Limited Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of isoleucyl tRNA synthetases
US8993723B2 (en) 2010-04-28 2015-03-31 Atyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of alanyl-tRNA synthetases
US9068177B2 (en) 2010-04-29 2015-06-30 Atyr Pharma, Inc Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of glutaminyl-tRNA synthetases
CA2797393C (en) 2010-04-29 2020-03-10 Atyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of valyl trna synthetases
JP6008838B2 (ja) 2010-04-29 2016-10-19 エータイアー ファーマ， インコーポレイテッド アスパラギニルｔＲＮＡ合成酵素のタンパク質フラグメントに関連した治療用、診断用および抗体組成物の革新的発見
EP2566496B1 (en) 2010-05-03 2018-02-28 aTyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of methionyl-trna synthetases
WO2011140132A2 (en) 2010-05-03 2011-11-10 Atyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of phenylalanyl-alpha-trna synthetases
EP2566516B1 (en) 2010-05-03 2019-07-03 aTyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of seryl-trna synthetases
JP5976638B2 (ja) 2010-05-03 2016-08-23 エータイアー ファーマ， インコーポレイテッド アルギニルｔＲＮＡ合成酵素のタンパク質フラグメントに関連した治療用、診断用および抗体組成物の革新的発見
CN103096909A (zh) 2010-05-04 2013-05-08 Atyr医药公司 与谷氨酰-脯氨酰-tRNA合成酶的蛋白片段相关的治疗、诊断和抗体组合物的创新发现
AU2011248101B2 (en) 2010-05-04 2016-10-20 Atyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of p38 multi-tRNA synthetase complex
US8945541B2 (en) 2010-05-14 2015-02-03 Atyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of phenylalanyl-beta-tRNA synthetases
WO2011146410A2 (en) 2010-05-17 2011-11-24 Atyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of leucyl-trna synthetases
US8962560B2 (en) 2010-06-01 2015-02-24 Atyr Pharma Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of Lysyl-tRNA synthetases
WO2012009289A2 (en) 2010-07-12 2012-01-19 Atyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of aspartyl-trna synthetases
AU2011289831C1 (en) 2010-07-12 2017-06-15 Pangu Biopharma Limited Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of glycyl-tRNA synthetases
US8999321B2 (en) 2010-07-12 2015-04-07 Atyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of glycyl-tRNA synthetases
US20130202576A1 (en) 2010-07-12 2013-08-08 Pangu Biopharma Limited Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of histidyl-trna synthetases
WO2012027611A2 (en) 2010-08-25 2012-03-01 Atyr Pharma, Inc. INNOVATIVE DISCOVERY OF THERAPEUTIC, DIAGNOSTIC, AND ANTIBODY COMPOSITIONS RELATED TO PROTEIN FRAGMENTS OF TYROSYL-tRNA SYNTHETASES
US9399770B2 (en) 2010-10-06 2016-07-26 Atyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of tryptophanyl-tRNA synthetases
WO2013022982A2 (en) 2011-08-09 2013-02-14 Atyr Pharma, Inc. Pegylated tyrosyl-trna synthetase polypeptides
WO2013086216A1 (en) 2011-12-06 2013-06-13 Atyr Pharma, Inc. Improved aspartyl-trna synthetases
WO2013086228A1 (en) 2011-12-06 2013-06-13 Atyr Pharma, Inc. Pegylated aspartyl-trna synthetase polypeptides
JP6169608B2 (ja) 2011-12-29 2017-07-26 エータイアー ファーマ， インコーポレイテッド アスパルチルｔＲＮＡシンテターゼ−Ｆｃコンジュゲート
US9248128B2 (en) 2012-01-27 2016-02-02 New York University Method for enhancing remyelination using GLI1 inhibitors
CA2873623C (en) * 2012-05-14 2021-11-09 Biogen Idec Ma Inc. Lingo-2 antagonists for treatment of conditions involving motor neurons
AU2014233436B2 (en) 2013-03-15 2019-12-05 Atyr Pharma, Inc. Histidyl-tRNA synthetase-Fc conjugates
JP2018504400A (ja) 2015-01-08 2018-02-15 バイオジェン・エムエイ・インコーポレイテッドＢｉｏｇｅｎ ＭＡ Ｉｎｃ． Ｌｉｎｇｏ‐１拮抗薬及び脱髄障害の治療のための使用
US10383080B2 (en) * 2015-01-26 2019-08-13 Intel IP Corporation Device and method to improve horizontal and vertical positioning accuracy
WO2018013714A1 (en) * 2016-07-13 2018-01-18 Biogen Ma Inc. Dosage regimens of lingo-1 antagonists and uses for treatment of demyelinating disorders
JP7679175B2 (ja) 2017-04-20 2025-05-19 エータイアー ファーマ， インコーポレイテッド 肺の炎症を治療するための組成物および方法
KR102414826B1 (ko) 2020-06-18 2022-06-30 삼성전기주식회사 코일 부품

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8308573D0 (en) 1983-03-29 1983-05-05 British Nuclear Fuels Ltd Filament impregnating/coating
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
EP0281604B1 (en) 1986-09-02 1993-03-31 Enzon Labs Inc. Single polypeptide chain binding molecules
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
CA2046632C (en) 1989-02-13 1999-05-11 Berthold Baldus Thrombolytic from vampire bat saliva
CN1798840B (zh) * 2003-03-19 2010-11-10 比奥根艾迪克Ma公司 Nogo受体结合蛋白
ES2537015T3 (es) * 2003-03-19 2015-06-01 Biogen Ma Inc. Proteína de unión del receptor de NOGO
US20050214288A1 (en) 2004-03-26 2005-09-29 Human Genome Sciences, Inc. Antibodies against Nogo receptor
EP1776136B1 (en) 2004-06-24 2012-10-03 Biogen Idec MA Inc. Treatment of conditions involving demyelination
DK1904104T3 (da) 2005-07-08 2013-11-11 Biogen Idec Inc SP35-antistoffer og anvendelser heraf

Also Published As

Publication number Publication date
CN103351437A (zh) 2013-10-16
MX2009005175A (es) 2009-08-07
CA2669181A1 (en) 2008-05-22
JP5647414B2 (ja) 2014-12-24
RU2009122514A (ru) 2010-12-27
JP2010509906A (ja) 2010-04-02
ZA200902409B (en) 2010-04-28
AR063829A1 (es) 2009-02-18
ECSP099332A (es) 2009-06-30
JP2013056888A (ja) 2013-03-28
CL2007003303A1 (es) 2008-06-27
ATE502960T1 (de) 2011-04-15
US20140255415A1 (en) 2014-09-11
CN101553506B (zh) 2013-08-07
IL198313A0 (en) 2011-08-01
EP2084190A1 (en) 2009-08-05
US20130071400A1 (en) 2013-03-21
AU2007321817A1 (en) 2008-05-22
DE602007013445D1 (de) 2011-05-05
EP2395022A9 (en) 2013-04-24
BRPI0718406A2 (pt) 2013-12-17
US20140037639A1 (en) 2014-02-06
CO6180433A2 (es) 2010-07-19
MA30965B1 (fr) 2009-12-01
CN101553506A (zh) 2009-10-07
WO2008058736A1 (en) 2008-05-22
TW200831534A (en) 2008-08-01
EP2395022A1 (en) 2011-12-14
US20100143362A1 (en) 2010-06-10
PE20081392A1 (es) 2008-11-12
ES2363622T3 (es) 2011-08-10
TN2009000190A1 (en) 2010-10-18
CR10756A (es) 2009-06-04
GT200900121A (es) 2011-11-11
KR20090078353A (ko) 2009-07-17
US8299221B2 (en) 2012-10-30
EP2084190B1 (en) 2011-03-23

Similar Documents

Publication Publication Date Title
NO20092331L (no) LINGO-bindingsmolekyler og farmasoytisk anvendelse derav
NO20064059L (no) Albumin fusjonsproteiner
WO2022026475A3 (en) Multimeric coronavirus binding molecules and uses thereof
BRPI0809594A2 (pt) polipeptídeo, seqüência de ácido nucléico, vetor, hospedeiro, processo para a produção de um polipeptídeo, composição farmacêutica, uso de um polipeptídeo, método para prevenção, tratamento ou melhora de uma doença, em um indivíduo com necessidade do mesmo, kit, método para a identificação de um polipeptídeo(s)
BRPI0511479A (pt) molécula de ligação tendo atividade neutralizadora do vìrus da raiva, variante funcional de uma molécula de ligação, imunoconjugado, molécula de ácido nucléico, vetor, hospedeiro, método para produzir uma molécula de ligação ou uma variante funcional, composição farmacêutica, uso de uma molécula de ligação, uma variante funcional, um imunoconjugado como, ou uma composição, kit, método para identificar uma molécula de ligação ou uma molécula de ácido nucléico, e, coleção de moléculas de ligação humanas na superfìcie de pacotes genéticos replicáveis
UA101155C2 (ru) Модифицированный полипептид фактора vii (fvii) и его применение
BRPI0614761A2 (pt) proteìnas de fusão de albumina
BR112014007469A2 (pt) arcabouços de proteína com base em repetição de fibronectina tipo iii com superfícies de ligação alternativas
WO2009117344A3 (en) Non-hydroxide base and protein denaturant hair straightening composition and process
WO2007054520A3 (en) Methods for the identification of microrna and their applications in research and human health
WO2011097181A3 (en) Compositions and methods for re-programming cells without genetic modification for treatment of neurological disorders
NO20092522L (no) Sammensetninger og fremgangsmater for a behandle kreft med cupredoxiner og CPG rikt DNA
WO2009152480A3 (en) Methods to treat solid tumors
NO20074944L (no) Heteroarylureaderivater anvendlige for inhibering av CHK1
WO2007053747A3 (en) Modulating endoplasmic reticulum stress in the treatment of tuberous sclerosis
WO2008040190A8 (fr) Petits peptides pour anti-angiogenèse et utilisation de ceux-ci
NO20061678L (no) NOGO-A bindingsmolekyler og funmsoytiske anvendelser derav
TN2010000199A1 (en) Improved nogo-a binding molecules and pharmaceutical use thereof
WO2010065069A3 (en) Compositions comprising renin-angiotensin aldosterone system inhibitors and lipoic acid compounds, and the use thereof for the treatment of renin-angiotensin aldosterone system related disorders
WO2009004632A3 (en) Methods of identifying components of a biological pathway and use of said components in regulating diseases associated with altered cell proliferation
WO2010036031A3 (en) Pauf-specific human monoclonal antibody, pharmaceutical composition for treating cancer comprising the same and method for detecting cancer using the same
WO2005121328A3 (en) Method for ameliorating an inflammatory skin condition
WO2007013358A3 (en) Vivit polypeptides, therapeutic agent comprising the same, and method of screening for anti-cancer agent
WO2006128025A3 (en) Regulatory proteins in lung repair and treatment of lung disease
WO2006014234A3 (en) Novel recombinant poxvirus composition and uses thereof

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application